Multiple Myeloma Research: Risks, benefits of stem cell transplant | Dana-Farber Cancer Institute

Dana-Farber research into autologous stem cell transplant for patients with multiple myeloma: study led by Dr. Paul G. Richardson, MD, found patients had dramatically increased progression-free survival, but were just as likely to be alive more than 6 years later if they chose to reserve their transplant until later. Press release: bit.ly/3cgaZ7l Video published: 7/14/22

Thank you so much Dana-Farber Cancer Institute. Greetings from Bimac Research Group, Universidad del Cauca, Colombia.

[@lexiconcapacitor586]

What kind of delay is the question

[@lexiconcapacitor586]

Whatabout it. Has anyone had this

[@avasworld1395]

My father is about to undergo stem cell transplant at the age of 64. Should he not proceed based on this study?

[@moffettcoates6455]

I’m 66, I had a stem cell transplant in May of 2023 at Duke Hospital in Durham, NC.